Charles S Cleeland

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3094669/publications.pdf

Version: 2024-02-01

211 papers	25,110 citations	14655 66 h-index	6996 154 g-index
216 all docs	216 docs citations	216 times ranked	21269 citing authors

#	Article	IF	Citations
1	Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations. Journal of Pain, 2008, 9, 105-121.	1.4	2,564
2	Pain and Its Treatment in Outpatients with Metastatic Cancer. New England Journal of Medicine, 1994, 330, 592-596.	27.0	1,920
3	Core outcome domains for chronic pain clinical trials: IMMPACT recommendations. Pain, 2003, 106, 337-345.	4.2	1,850
4	The rapid assessment of fatigue severity in cancer patients. Cancer, 1999, 85, 1186-1196.	4.1	1,482
5	When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain, 1995, 61, 277-284.	4.2	1,265
6	Assessing symptom distress in cancer patients. Cancer, 2000, 89, 1634-1646.	4.1	1,156
7	Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Journal of the National Cancer Institute, 2014, 106, dju244-dju244.	6.3	689
8	Validity and Reliability of the US National Cancer Instituteâ€™s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). JAMA Oncology, 2015, 1, 1051.	7.1	581
9	Clinical Evaluation of Once-Weekly Dosing of Epoetin Alfa in Chemotherapy Patients: Improvements in Hemoglobin and Quality of Life Are Similar to Three-Times-Weekly Dosing. Journal of Clinical Oncology, 2001, 19, 2875-2882.	1.6	574
10	Baseline quality of life as a prognostic indicator of survival: a meta-analysis of individual patient data from EORTC clinical trials. Lancet Oncology, The, 2009, 10, 865-871.	10.7	519
11	Pain and Treatment of Pain in Minority Patients with Cancer: The Eastern Cooperative Oncology Group Minority Outpatient Pain Study. Annals of Internal Medicine, 1997, 127, 813.	3.9	472
12	Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism?. Cancer, 2003, 97, 2919-2925.	4.1	460
13	Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer, 2002, 95, 888-895.	4.1	398
14	Symptom Burden: Multiple Symptoms and Their Impact as Patient-Reported Outcomes. Journal of the National Cancer Institute Monographs, 2007, 2007, 16-21.	2.1	341
15	Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 977-1007.	4.9	298
16	Stereotactic body radiation therapy for management of spinal metastases in patients without spinal cord compression: a phase 1â€“2 trial. Lancet Oncology, The, 2012, 13, 395-402.	10.7	289
17	Automated Symptom Alerts Reduce Postoperative Symptom Severity After Cancer Surgery: A Randomized Controlled Clinical Trial. Journal of Clinical Oncology, 2011, 29, 994-1000.	1.6	280
18	A Cytokine-Based Neuroimmunologic Mechanism of Cancer-Related Symptoms. NeuroImmunoModulation, 2004, 11, 279-292.	1.8	266

#	Article	IF	Citations
19	Prevalence and characteristics of moderate to severe fatigue: A multicenter study in cancer patients and survivors. Cancer, 2014, 120, 425-432.	4.1	259
20	Prospective, Observational Study of Pain and Analgesic Prescribing in Medical Oncology Outpatients With Breast, Colorectal, Lung, or Prostate Cancer. Journal of Clinical Oncology, 2012, 30, 1980-1988.	1.6	244
21	The symptom burden of cancer: Evidence for a core set of cancerâ€related and treatmentâ€related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer, 2013, 119, 4333-4340.	4.1	235
22	Measuring head and neck cancer symptom burden: The development and validation of the M. D. Anderson symptom inventory, head and neck module. Head and Neck, 2007, 29, 923-931.	2.0	227
23	Cancer pain management among underserved minority outpatients. Cancer, 2002, 94, 2295-2304.	4.1	226
24	Symptom burden in cancer survivors 1 year after diagnosis. Cancer, 2011, 117, 2779-2790.	4.1	226
25	Dimensions of the impact of cancer pain in a four country sample: new information from multidimensional scaling. Pain, 1996, 67, 267-273.	4.2	219
26	Impact of pain on self-rated health in the community-dwelling older adults. Pain, 2002, 95, 75-82.	4.2	211
27	Patient Self-Reports of Symptoms and Clinician Ratings as Predictors of Overall Cancer Survival. Journal of the National Cancer Institute, 2011, 103, 1851-1858.	6.3	196
28	Public attitudes toward cancer pain. Cancer, 1985, 56, 2337-2339.	4.1	184
29	Analyzing multiple endpoints in clinical trials of pain treatments: IMMPACT recommendations. Pain, 2008, 139, 485-493.	4.2	179
30	Chinese version of the M. D. Anderson Symptom Inventory. Cancer, 2004, 101, 1890-1901.	4.1	165
31	Factors influencing physician management of cancer pain. Cancer, 1986, 58, 796-800.	4.1	159
32	Cancer- and Chemotherapy-Induced Anemia. Journal of the National Comprehensive Cancer Network: JNCCN, 2012, 10, 628-653.	4.9	153
33	Inflammatory cytokines are associated with the development of symptom burden in patients with NSCLC undergoing concurrent chemoradiation therapy. Brain, Behavior, and Immunity, 2010, 24, 968-974.	4.1	150
34	Adult Cancer Pain. Journal of the National Comprehensive Cancer Network: JNCCN, 2013, 11, 992-1022.	4.9	144
35	Cancer-related symptoms. Seminars in Radiation Oncology, 2000, 10, 175-190.	2.2	128
36	Undertreatment of Cancer Pain in Elderly Patients. JAMA - Journal of the American Medical Association, 1998, 279, 1914.	7.4	127

#	Article	IF	Citations
37	Japanese version of the M.D. Anderson Symptom Inventory: A validation study. Journal of Pain and Symptom Management, 2003, 26, 1093-1104.	1.2	127
38	Pain outcomes in patients with advanced breast cancer and bone metastases. Cancer, 2013, 119, 832-838.	4.1	126
39	Patient-Reported Outcomes: Instrument Development and Selection Issues. Value in Health, 2007, 10, S86-S93.	0.3	122
40	Intensity Modulated Proton Therapy Versus Intensity Modulated Photon Radiation Therapy for Oropharyngeal Cancer: First Comparative Results of Patient-Reported Outcomes. International Journal of Radiation Oncology Biology Physics, 2016, 95, 1107-1114.	0.8	121
41	Translational approaches to treatment-induced symptoms in cancer patients. Nature Reviews Clinical Oncology, 2012, 9, 414-426.	27.6	115
42	ASCPRO Recommendations for theÂAssessment ofÂFatigue as an Outcome inÂClinical Trials. Journal of Pain and Symptom Management, 2010, 39, 1086-1099.	1.2	112
43	Longitudinal Study of the Relationship Between Chemoradiation Therapy for Nonâ€“Small-Cell Lung Cancer and Patient Symptoms. Journal of Clinical Oncology, 2006, 24, 4485-4491.	1.6	108
44	Patterns of symptom burden during radiotherapy or concurrent chemoradiotherapy for head and neck cancer: A prospective analysis using the University of Texas MD Anderson Cancer Center Symptom Inventoryâ€Head and Neck Module. Cancer, 2014, 120, 1975-1984.	4.1	106
45	Pain, Depression, and Fatigue in Community-Dwelling Adults With and Without a History of Cancer. Journal of Pain and Symptom Management, 2006, 32, 118-128.	1.2	105
46	The effects of pain severity on health-related quality of life. Cancer, 1999, 86, 1848-1855.	4.1	104
47	Asking the Community About Cutpoints Used to Describe Mild, Moderate, and Severe Pain. Journal of Pain, 2006, 7, 49-56.	1.4	102
48	Caregiver symptom burden: The risk of caring for an underserved patient with advanced cancer. Cancer, 2011, 117, 1070-1079.	4.1	102
49	Reducing the toxicity of cancer therapy: recognizing needs, taking action. Nature Reviews Clinical Oncology, 2012, 9, 471-478.	27.6	102
50	The Measurement of Pain from Metastatic Bone Disease: Capturing the Patient's Experience. Clinical Cancer Research, 2006, 12, 6236s-6242s.	7.0	100
51	Measuring the Symptom Burden of Lung Cancer: The Validity and Utility of the Lung Cancer Module of the M. D. Anderson Symptom Inventory. Oncologist, 2011, 16, 217-227.	3.7	99
52	Symptoms and Quality of Life in Diverse Patients Undergoing Hematopoietic Stem Cell Transplantation. Journal of Pain and Symptom Management, 2012, 44, 168-180.	1.2	99
53	Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain, Behavior, and Immunity, 2012, 26, 699-705.	4.1	94
54	Symptom recovery after thoracic surgery: Measuring patient-reported outcomes with the MD Anderson Symptom Inventory. Journal of Thoracic and Cardiovascular Surgery, 2015, 150, 613-619.e2.	0.8	92

#	Article	IF	Citations
55	Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood, 2013, 122, 641-647.	1.4	91
56	Validation study of the Chinese version of the Brief Fatigue Inventory (BFI-C). Journal of Pain and Symptom Management, 2004, 27, 322-332.	1.2	84
57	Patient-Reported Outcome Measures in Safety Event Reporting: PROSPER Consortium Guidance. Drug Safety, 2013, 36, 1129-1149.	3.2	84
58	Cancer pain management by radiotherapists: a survey of radiation therapy oncology group physicians. International Journal of Radiation Oncology Biology Physics, 2000, 47, 203-208.	0.8	83
59	Pain and health-related quality of life in patients with advanced solid tumours and bone metastases: integrated results from three randomized, double-blind studies of denosumab and zoledronic acid. Supportive Care in Cancer, 2013, 21, 3497-3507.	2.2	80
60	Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASIâ€GI). Cancer, 2010, 116, 2053-2063.	4.1	79
61	Informing the Tolerability of Cancer Treatments Using Patient-Reported Outcome Measures: Summary of an FDA and Critical Path Institute Workshop. Value in Health, 2018, 21, 742-747.	0.3	79
62	Assessing the Symptoms of Cancer Using Patient-Reported Outcomes (ASCPRO): Searching forÂStandards. Journal of Pain and Symptom Management, 2010, 39, 1077-1085.	1.2	77
63	A Randomized, Double-blind, 2-Period, Placebo-Controlled Crossover Trial of a Sustained-Release Methylphenidate in the Treatment of Fatigue in Cancer Patients. Cancer Journal (Sudbury, Mass), 2014, 20, 8-14.	2.0	76
64	Taiwanese Version of the M. D. Anderson Symptom Inventory: Symptom Assessment in Cancer Patients. Journal of Pain and Symptom Management, 2007, 33, 180-188.	1.2	75
65	Rapid Improvement in Pain Management: The Veterans Health Administration and the Institute for Healthcare Improvement Collaborative. Clinical Journal of Pain, 2003, 19, 298-305.	1.9	73
66	The M. D. Anderson Symptom Inventoryâ€“Head and Neck Module, a Patient-Reported Outcome Instrument, Accurately Predicts the Severity of Radiation-Induced Mucositis. International Journal of Radiation Oncology Biology Physics, 2008, 72, 1355-1361.	0.8	72
67	Serum interleukinâ€6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation. Cancer, 2008, 113, 2102-2109.	4.1	71
68	Symptom burden in cancer survivorship. Journal of Cancer Survivorship, 2007, 1, 167-175.	2.9	68
69	Content Validity of Self-Report Measurement Instruments: An Illustration From the Development of the Brain Tumor Module of the M.D. Anderson Symptom Inventory. Oncology Nursing Forum, 2005, 32, 669-676.	1.2	66
70	Validation Study of the Korean Version of the M. D. Anderson Symptom Inventory. Journal of Pain and Symptom Management, 2006, 31, 345-352.	1.2	64
71	Prognostic value of symptom burden for overall survival in patients receiving chemotherapy for advanced nonsmall cell lung cancer. Cancer, 2010, 116, 137-145.	4.1	61
72	Pain and analgesic use associated with skeletal-related events in patients with advanced cancer and bone metastases. Supportive Care in Cancer, 2016, 24, 1327-1337.	2.2	61

#	Article	IF	Citations
73	Validating the M. D. Anderson Symptom Inventory (MDASI) for use in patients with ovarian cancer. Gynecologic Oncology, 2013, 130, 323-328.	1.4	60
74	Adequacy of Cancer Pain Management in a Japanese Cancer Hospital. Japanese Journal of Clinical Oncology, 2004, 34, 37-42.	1.3	58
75	Evaluation of different recall periods for the US National Cancer Instituteâ€™s PRO-CTCAE. Clinical Trials, 2017, 14, 255-263.	1.6	58
76	Inflammatory Markers and Development of Symptom Burden in Patients with Multiple Myeloma during Autologous Stem Cell Transplantation. Clinical Cancer Research, 2014, 20, 1366-1374.	7.0	57
77	The symptom burden of treatmentâ€naive patients with head and neck cancer. Cancer, 2015, 121, 766-773.	4.1	56
78	Assessment of clinical relevant fatigue level in cancer. Supportive Care in Cancer, 2007, 15, 891-896.	2.2	53
79	Acute cognitive impairment in patients with multiple myeloma undergoing autologous hematopoietic stem cell transplant. Cancer, 2013, 119, 4188-4195.	4.1	53
80	Brief cognitive-behavioral audiotape interventions for cancer-related pain. Cancer, 2006, 107, 207-214.	4.1	52
81	Assessment of Cancer-Related Neuropathy and Neuropathic Pain. Oncologist, 2010, 15, 13-18.	3.7	50
82	Impact of symptom burden on work-related abilities in patients with locally recurrent or metastatic breast cancer: Results from a substudy of the VIRGO observational cohort study. Breast, 2014, 23, 763-769.	2.2	50
83	Sleep quality and its association with fatigue, symptom burden, and mood in patients with advanced cancer in a clinic for earlyâ€phase oncology clinical trials. Cancer, 2016, 122, 3401-3409.	4.1	50
84	Greek M.D. Anderson Symptom Inventory: Validation and Utility in Cancer Patients. Oncology, 2004, 67, 203-210.	1.9	49
85	Cancer-Related Symptom Assessment in Russia: Validation and Utility of the Russian M. D. Anderson Symptom Inventory. Journal of Pain and Symptom Management, 2005, 30, 443-453.	1.2	49
86	The Establishment of the GENEQOL Consortium to Investigate the Genetic Disposition of Patient-Reported Quality-of-Life Outcomes. Twin Research and Human Genetics, 2009, 12, 301-311.	0.6	48
87	High symptom burden prior to radiation therapy for head and neck cancer: A patientâ€reported outcomes study. Head and Neck, 2013, 35, 1490-1498.	2.0	48
88	Development and Initial Validation of the Thyroid Cancer Module of the M. D. Anderson Symptom Inventory. Oncology, 2009, 76, 59-68.	1.9	46
89	Recommendations for including multiple symptoms as endpoints in cancer clinical trials. Cancer, 2013, 119, 411-420.	4.1	46
90	Impact of Cultural and Linguistic Factors on Symptom Reporting by Patients With Cancer. Journal of the National Cancer Institute, 2010, 102, 732-738.	6.3	44

#	Article	IF	Citations
91	Validation of the M. D. Anderson Symptom Inventory multiple myeloma module. Journal of Hematology and Oncology, 2013, 6, 13.	17.0	42
92	Filipino Version of the M. D. Anderson Symptom Inventory: Validation and Multisymptom Measurement in Cancer Patients. Journal of Pain and Symptom Management, 2006, 31, 542-552.	1.2	41
93	Symptom burden after autologous stem cell transplantation for multiple myeloma. Cancer, 2008, 112, 1617-1624.	4.1	40
94	Clinical Utility of the MDASI-BT in Patients with Brain Metastases. Journal of Pain and Symptom Management, 2009, 37, 331-340.	1.2	38
95	Using group-based trajectory modeling to examine heterogeneity of symptom burden in patients with head and neck cancer undergoing aggressive non-surgical therapy. Quality of Life Research, 2013, 22, 2331-2339.	3.1	38
96	Assessment of baseline symptom burden in treatment-naÃ¯ve patients with lung cancer: an observational study. Supportive Care in Cancer, 2019, 27, 3439-3447.	2.2	38
97	Psychometric Testing of the MDASI-HF: A Symptom Assessment Instrument for Patients With Cancer and Concurrent Heart Failure. Journal of Cardiac Failure, 2008, 14, 497-507.	1.7	37
98	Levels of Symptom Burden During Chemotherapy for Advanced Lung Cancer: Differences Between Public Hospitals and a Tertiary Cancer Center. Journal of Clinical Oncology, 2011, 29, 2859-2865.	1.6	37
99	Changes in Pain and Other Symptoms in Patients With Painful Multiple Myeloma-Related Vertebral Fracture Treated With Kyphoplasty or Vertebroplasty. Journal of Pain, 2012, 13, 564-570.	1.4	37
100	Subclinical Peripheral Neuropathy in Patients With Multiple Myeloma Before Chemotherapy Is Correlated With Decreased Fingertip Innervation Density. Journal of Clinical Oncology, 2014, 32, 3156-3162.	1.6	37
101	When is it justified to treat symptoms? Measuring symptom burden. Oncology, 2002, 16, 64-70.	0.5	37
102	Reliability and validity of the M. D. Anderson Symptom Inventoryâ€“Spine Tumor Module. Journal of Neurosurgery: Spine, 2010, 12, 421-430.	1.7	36
103	Patient-Reported Symptom Interference as a Measure of Postsurgery Functional Recovery in Lung Cancer. Journal of Pain and Symptom Management, 2016, 52, 822-831.	1.2	36
104	The impact of symptom interference using the MD Anderson Symptom Inventoryâ€Brain Tumor Module (MDASIâ€BT) on prediction of recurrence in primary brain tumor patients. Cancer, 2011, 117, 3222-3228.	4.1	35
105	Working after a metastatic cancer diagnosis: Factors affecting employment in the metastatic setting from ECOGâ€ACRIN's Symptom Outcomes and Practice Patterns study. Cancer, 2016, 122, 438-446.	4.1	35
106	Validation of the Persian Version of the Brief Pain Inventory (BPI-P) in Chronic Pain Patients. Journal of Pain and Symptom Management, 2017, 54, 132-138.e2.	1.2	35
107	Cancer-Related Symptom Assessment in France: Validation of the French M. D. Anderson Symptom Inventory. Journal of Pain and Symptom Management, 2010, 39, 721-733.	1.2	34
108	Biological pathways and genetic variables involved in pain. Quality of Life Research, 2010, 19, 1407-1417.	3.1	33

#	Article	IF	Citations
109	The Validity and Utility of the M. D. Anderson Symptom Inventory in Patients With Breast Cancer: Evidence From the Symptom Outcomes and Practice Patterns Data From the Eastern Cooperative Oncology Group. Clinical Breast Cancer, 2013, 13, 325-334.	2.4	33
110	Burden of symptoms associated with development of metastatic bone disease in patients with breast cancer. Supportive Care in Cancer, 2016, 24, 3557-3565.	2.2	32
111	A Preliminary Study of the Utility of the Brief Hospice Inventory. Journal of Pain and Symptom Management, 2001, 22, 637-648.	1.2	31
112	The Validity and Utility of the MD Anderson Symptom Inventory in Patients With Prostate Cancer: Evidence From the Symptom Outcomes and Practice Patterns (SOAPP) Data From the Eastern Cooperative Oncology Group. Clinical Genitourinary Cancer, 2014, 12, 41-49.	1.9	31
113	Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents. Supportive Care in Cancer, 2015, 23, 1157-1168.	2.2	31
114	Assessing symptom burden using the M. D. Anderson symptom inventory in patients with chemotherapyâ€induced anemia. Cancer, 2007, 110, 1629-1640.	4.1	30
115	Pain and Fatigue in Community-Dwelling Adults. Pain Medicine, 2003, 4, 231-237.	1.9	29
116	Validation and Application of the Arabic Version of the M. D. Anderson Symptom Inventory in Moroccan Patients With Cancer. Journal of Pain and Symptom Management, 2010, 40, 75-86.	1.2	29
117	Longitudinal analysis of patient-reported symptoms post-autologous stem cell transplant and their relationship to inflammation in patients with multiple myeloma. Leukemia and Lymphoma, 2015, 56, 1335-1341.	1.3	29
118	The analgesic effects that underlie patient satisfaction with treatment. Pain, 2004, 110, 480-487.	4.2	28
119	Does Recall Period Have an Effect on Cancer Patients' Ratings of the Severity of Multiple Symptoms?. Journal of Pain and Symptom Management, 2010, 40, 191-199.	1.2	27
120	Congruence of primary brain tumor patient and caregiver symptom report. Cancer, 2012, 118, 5026-5037.	4.1	27
121	Anastrozole-Associated Joint Pain and Other Symptoms in Patients With Breast Cancer. Journal of Pain, 2013, 14, 290-296.	1.4	27
122	Automated pain intervention for underserved minority women with breast cancer. Cancer, 2015, 121, 1882-1890.	4.1	27
123	Prospective Study of Patient-Reported Symptom Burden in Patients With Nonâ€“Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. Journal of Pain and Symptom Management, 2016, 51, 832-838.	1.2	27
124	An exploration of differences between Japan and two European countries in the self-reporting and valuation of pain and discomfort on the EQ-5D. Quality of Life Research, 2017, 26, 2067-2078.	3.1	27
125	A fatigue clinic in a comprehensive cancer center. Cancer, 2001, 92, 1708-1713.	4.1	26
126	Assessing Cancer Symptoms in Adolescents With Cancer Using the Taiwanese Version of the M. D. Anderson Symptom Inventory. Cancer Nursing, 2008, 31, E9-E16.	1.5	26

#	Article	IF	Citations
127	Assessment of Fatigue in Cancer Patients and Community Dwellers: Validation Study of the Filipino Version of the Brief Fatigue Inventory. Oncology, 2010, 79, 112-117.	1.9	26
128	Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. Oncology, 2016, 90, 127-135.	1.9	25
129	Long-term patient reported outcomes following radiation therapy for oropharyngeal cancer: cross-sectional assessment of a prospective symptom survey in patients â‰¥65Âyears old. Radiation Oncology, 2017, 12, 150.	2.7	25
130	Measuring Therapy-Induced Peripheral Neuropathy: Preliminary Development and Validation of the Treatment-Induced Neuropathy Assessment Scale. Journal of Pain, 2015, 16, 1032-1043.	1.4	23
131	Racial/ethnic disparities in inflammatory gene singleâ€nucleotide polymorphisms as predictors of a high risk for symptom burden in patients with multiple myeloma 1 year after diagnosis. Cancer, 2015, 121, 1138-1146.	4.1	23
132	Pediatric Cancer Pain Management Practices and Attitudes in China. Journal of Pain and Symptom Management, 2003, 26, 748-759.	1.2	22
133	Temporal Patterns of Fatigue Predict Pathologic Response in Patients Treated With Preoperative Chemoradiation Therapy for Rectal Cancer. International Journal of Radiation Oncology Biology Physics, 2009, 75, 775-781.	0.8	22
134	Efficacy of the Natural Clay, Calcium Aluminosilicate Anti-Diarrheal, in Reducing Medullary Thyroid Cancerâ€"Related Diarrhea and Its Effects on Quality of Life: A Pilot Study. Thyroid, 2015, 25, 1085-1090.	4.5	22
135	Psychometric Properties of the Brief Fatigue Inventory in Greek Patients with Advanced Cancer. Journal of Pain and Symptom Management, 2008, 36, 367-373.	1.2	21
136	Prognostic value of patient-reported symptom interference in patients with late-stage lung cancer. Quality of Life Research, 2013, 22, 2143-2150.	3.1	21
137	Capturing the Patient's Experience: Using Qualitative Methods to Develop a Measure of Patient-Reported Symptom Burden: An Example From Ovarian Cancer. Journal of Pain and Symptom Management, 2013, 46, 837-845.	1.2	20
138	Validity and Reliability of the Indonesian Version of the Brief Fatigue Inventory in Cancer Patients. Journal of Pain and Symptom Management, 2016, 52, 744-751.	1.2	20
139	Software for Administering the National Cancer Instituteâ€™s Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events: Usability Study. JMIR Human Factors, 2018, 5, e10070.	2.0	20
140	The Behavior of Normal and Stomach Lesion Susceptible Rats in Several Learning Situations. Journal of Genetic Psychology, 1963, 102, 91-94.	1.2	19
141	Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Nonâ€"Small-Cell Lung Cancer: Treatment Setting and Minority Status Do Not Make a Difference. Journal of Thoracic Oncology, 2014, 9, 1459-1463.	1.1	19
142	Improving attribution of adverse events in oncology clinical trials. Cancer Treatment Reviews, 2019, 76, 33-40.	7.7	19
143	Nomogram for Predicting Symptom Severity during Radiation Therapy for Head and Neck Cancer. Otolaryngology - Head and Neck Surgery, 2014, 151, 619-626.	1.9	18
144	Ruxolitinib for symptom control in patients with chronic lymphocytic leukaemia: a single-group, phase 2 trial. Lancet Haematology,the, 2017, 4, e67-e74.	4.6	18

#	Article	IF	Citations
145	Interpreting Patient-reported Outcome Scores for Clinical Research and Practice. Medical Care, 2019, 57, S8-S12.	2.4	18
146	Predictors of significant worsening of patientâ€•reported fatigue over a 1â€•month timeframe in ambulatory patients with common solid tumors. Cancer, 2014, 120, 442-450.	4.1	17
147	Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. Journal of Pain and Symptom Management, 2019, 58, 662-671.	1.2	17
148	Introduction. Cancer, 2001, 92, 1657-1661.	4.1	16
149	Using a symptom-specific instrument to measure patient-reported daily functioning in patients with cancer. European Journal of Cancer, 2016, 67, 83-90.	2.8	16
150	Cancer Pain: Progress Since the WHO Guidelines. Pain Practice, 2001, 1, 236-242.	1.9	15
151	Pain and Suffering During Cancer Therapy: Continued Sins of Omission. International Journal of Radiation Oncology Biology Physics, 2008, 72, 6-8.	0.8	15
152	Integrating Pain Metrics into Oncology Clinical Trials. Clinical Cancer Research, 2011, 17, 6646-6650.	7.0	15
153	Subclinical pretreatment sensory deficits appear to predict the development of pain and numbness in patients with multiple myeloma undergoing chemotherapy. Cancer Chemotherapy and Pharmacology, 2013, 71, 1531-1540.	2.3	15
154	Symptom Burden of Cancer Patients: Validation of the German M. D. Anderson Symptom Inventory: A Cross-Sectional Multicenter Study. Journal of Pain and Symptom Management, 2015, 49, 117-125.	1.2	15
155	Higher Stem Cell Dose Infusion after Intensive Chemotherapy Does Not Improve Symptom Burden in Older Patients with Multiple Myeloma and Amyloidosis. Biology of Blood and Marrow Transplantation, 2016, 22, 226-231.	2.0	15
156	Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial. International Journal of Radiation Oncology Biology Physics, 2020, 106, 100-107.	0.8	15
157	Symptom burden and its functional impact in patients with â€œsymptomaticâ€•relapsed or refractory multiple myeloma. Supportive Care in Cancer, 2021, 29, 467-475.	2.2	15
158	Health Care Providers' Assessments of the Quality of Advanced-Cancer Care in Latin American Medical Institutions: A Comparison of Predictors in Five Countries: Argentina, Brazil, Cuba, Mexico, and Peru. Journal of Pain and Palliative Care Pharmacotherapy, 2008, 22, 7-20.	0.8	14
159	Symptom burden in hematologic malignancies. Blood, 2014, 123, 3686-3687.	1.4	13
160	Cancer Pain: Progress Since the WHO Guidelines. Pain Practice, 2001, 1, 236-242.	1.9	13
161	Cancer-Related Internet Use and Its Association With Patient Decision Making and Trust in Physicians Among Patients in an Early Drug Development Clinic: A Questionnaire-Based Cross-Sectional Observational Study. Journal of Medical Internet Research, 2019, 21, e10348.	4.3	13
162	Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. Expert Review of Pharmacoeconomics and Outcomes Research, 2011, 11, 587-599.	1.4	12

#	Article	IF	Citations
163	Screening for Depressed Mood in Patients With Cancer Using the MD Anderson Symptom Inventory: Investigation of a Practical Approach for the Oncologist. Journal of Oncology Practice, 2014, 10, e95-e102.	2.5	12
164	Patient-reported lung symptoms as an early signal of impending radiation pneumonitis in patients with non-small cell lung cancer treated with chemoradiation: an observational study. Quality of Life Research, 2018, 27, 1563-1570.	3.1	12
165	Validation and application of a module of the MD Anderson Symptom Inventory for measuring perioperative symptom burden in patients with gynecologic cancer (the MDASI-PeriOp-GYN). Gynecologic Oncology, 2019, 152, 492-500.	1.4	12
166	Minocycline for symptom reduction during radiation therapy for head and neck cancer: a randomized clinical trial. Supportive Care in Cancer, 2020, 28, 261-269.	2.2	12
167	The Association between Symptom Burdens and Utility in Chinese Cancer Patients. Quality of Life Research, 2006, 15, 1427-1438.	3.1	11
168	Modification of existing patient-reported outcome measures: qualitative development of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). Quality of Life Research, 2018, 27, 3229-3241.	3.1	11
169	Evaluating the psychometric properties of the Immunotherapy module of the MD Anderson Symptom Inventory. , 2020, 8, e000931.		11
170	Psychometric Validation of the M. D. Anderson Symptom Inventoryâ€“Head and Neck Module in the Spanish Language. Journal of Pain and Symptom Management, 2016, 51, 1055-1061.	1.2	9
171	Concept domain validation and item generation for the Treatment-Induced Neuropathy Assessment Scale (TNAS). Supportive Care in Cancer, 2019, 27, 1021-1028.	2.2	8
172	What Do Patients With Nonâ€“Small-Cell Lung Cancer Experience? Content Domain for the MD Anderson Symptom Inventory for Lung Cancer. JCO Oncology Practice, 2020, 16, e1151-e1160.	2.9	8
173	A Patient-Reported Outcome Measure for Symptoms and Symptom Burden of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS). Blood, 2015, 126, 2094-2094.	1.4	8
174	Assessment of physical function by subjective and objective methods in patients undergoing open gynecologic surgery. Gynecologic Oncology, 2021, 161, 83-88.	1.4	7
175	Identification of Breast Cancer Survivors With High Symptom Burden. Cancer Nursing, 2022, 45, 253-261.	1.5	7
176	Evaluation of the psychometric properties and minimally important difference of the MD Anderson Symptom Inventory for malignant pleural mesothelioma (MDASI-MPM). Journal of Patient-Reported Outcomes, 2019, 3, 34.	1.9	6
177	Validation study of the Japanese version of MD Anderson Symptom Inventory for Brain Tumor module. Japanese Journal of Clinical Oncology, 2020, 50, 787-793.	1.3	6
178	Establishment of Minimal Clinically Important Improvement for Patient-Reported Symptoms to Define Recovery After Video-Assisted Thoracoscopic Surgery. Annals of Surgical Oncology, 2022, 29, 5593-5604.	1.5	6
179	Enhancing quality of life as a goal for anticancer therapeutics. Science Translational Medicine, 2016, 8, 344ed9.	12.4	5
180	Utility of a patient-reported outcome in measuring functional impairment during autologous stem cell transplant in patients with multiple myeloma. Quality of Life Research, 2018, 27, 979-985.	3.1	5

#	Article	IF	Citations
181	Cancer-Related Internet Use and Online Social Networking Among Patients in an Early-Phase Clinical Trials Clinic at a Comprehensive Cancer Center. JCO Clinical Cancer Informatics, 2018, 2, 1-14.	2.1	5
182	Removal and insertion of central venous catheters in cancer patients is associated with high symptom burden. Expert Review of Medical Devices, 2018, 15, 591-596.	2.8	5
183	Testing Symptom Severity Thresholds and Potential Alerts for Clinical Intervention in Patients With Cancer Undergoing Chemotherapy. JCO Oncology Practice, 2020, 16, e893-e901.	2.9	5
184	A Randomized, Placebo-Controlled, Double-Blind Study of Minocycline for Reducing the Symptom Burden Experienced by Patients With Advanced Pancreatic Cancer. Journal of Pain and Symptom Management, 2020, 59, 1052-1058.e1.	1.2	5
185	Development of a patient-reported outcome tool for assessing symptom burden during perioperative care in liver surgery: The MDASI-PeriOp-Hep. European Journal of Oncology Nursing, 2021, 52, 101959.	2.1	5
186	The Treatment-induced Neuropathy Assessment Scale (TNAS): a psychometric update following qualitative enrichment. Journal of Patient-Reported Outcomes, 2020, 4, 15.	1.9	5
187	Mechanisms of treatment-related symptoms in cancer patients. European Journal of Cancer, Supplement, 2013, 11, 301-302.	2.2	3
188	Measuring symptoms as a critical component of drug development and evaluation in hematological diseases. Clinical Investigation, 2013, 3, 1127-1138.	0.0	3
189	Minocycline for symptom reduction in patients with multiple myeloma during maintenance therapy: a phase II placebo-controlled randomized trial. Supportive Care in Cancer, 2021, 29, 6099-6107.	2.2	3
190	Developing translational animal models of cancer-related fatigue. , 2010, , 124-141.		3
191	Psychometric validity and reliability of the Danish version of the MD Anderson Symptom Inventory Brain Tumor Module. Neuro-Oncology Practice, 2021, 8, 137-147.	1.6	3
192	Shortness of Breath on Day 1 After Surgery Alerting the Presence of Early Respiratory Complications After Surgery in Lung Cancer Patients. Patient Preference and Adherence, 2022, Volume 16, 709-722.	1.8	3
193	Patient-reported outcomes in light of supportive medications in treatment-naÃ¯ve lung cancer patients. Supportive Care in Cancer, 2020, 28, 1809-1816.	2.2	2
194	Preferences of Individuals With Cancer for Patient-Reported Outcome Measures. Oncology Nursing Forum, 2021, 48, 173-183.	1.2	2
195	Linguistic Validation of the Turkish Version of the M.D. Anderson Symptom Inventory - Head and Neck Cancer Module. Balkan Medical Journal, 2016, 33, 339-343.	0.8	2
196	Linguistic validation of the Greek M.D. Anderson Symptom Inventory - Head and Neck Module. , 2012, 3, 29-31.		2
197	Symptom measurement by patient report. , 2010, , 268-284.		2
198	Factors affecting symptom presentation in an early-phase clinical trials clinic patient population. Investigational New Drugs, 2020, 38, 1166-1174.	2.6	1

#	Article	IF	Citations
199	A new symptom measure in gastrointestinal stomal tumors.. Journal of Clinical Oncology, 2013, 31, e17508-e17508.	1.6	1
200	Epidemiology of Pain and Cancer-Related Symptoms. , 2005, , 1029-1037.		1
201	Introduction to cancer symptom science. , 0, , 1-3.		1
202	World conference for cancer organisations march 3-7, 1996, melbourne, australia. Cancer, 1998, 82, 234-234.	4.1	0
203	Symptom Assessment. , 2005, , 991-1004.		0
204	Cytokines and sickness behavior: a model for cancer symptoms. , 0, , 8-17.		0
205	From inflammation to sickness and depression: the cytokine connection. , 0, , 95-109.		0
206	Cancer-related fatigue: clinical science. , 0, , 110-123.		0
207	Genetic approaches to treating and preventing symptoms in patients with cancer. , 0, , 192-205.		0
208	High-dose therapy and posttransplantation symptom burden: striking a balance. , 0, , 224-236.		0
209	Bayesian adaptive design: a novel approach to test the effectiveness of symptom-reducing agents using patient-reported outcomes. , 0, , 293-303.		0
210	Developing symptom management drugs. , 0, , 314-324.		0
211	Symptom research: looking ahead. , 0, , 341-348.		0